Gimatecan, a novel camptothecin with a promising preclinical profile

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 545-552

  Pratesi, Graziella ^a   Beretta, Giovanni L ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Camptothecin; Gimatecan; Preclinical profile

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; GIMATECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW TOXICITY; CELL FUNCTION; CROSS RESISTANCE; DIARRHEA; DNA HELIX; DNA MODIFICATION; DNA STRAND; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; GRANULOCYTOPENIA; HUMAN; IC 50; LIPOPHILICITY; MAXIMUM TOLERATED DOSE; METASTASIS INHIBITION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; THROMBOCYTOPENIA; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MULTICENTER STUDIES;

EID: 3142729057     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131687.08175.14     Document Type: Review

References (39)

1. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998; 1400:107-119.
2. Giovannella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246:1046-1048.
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-374.
4. Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX-8951F, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998; 42:210-220.
5. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and Phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann NY Acad Sci 2000; 922:324-325.
6. Zunino F, Dallavalle S, Laccabue D, Beretta G, Merlini L, Pratesi G. Current status and perspectives in the development of camptothecins. Curr Pharm Des 2002; 8:2505-2520.
7. Bom D, Curran DP, Kruszewski S, Zimmer SG, Strode JT, Kohlhagen G et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000; 43:3970-3980.
8. Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 2001; 48:83-87.
9. Dallavalle S, Delsoldato T, Ferrari A, Merlini L, Penco S, Carenini N, et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 2000; 43:3963-3969.
10. Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999; 59:2939-2943.
11. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37:40-46.
12. Sugimori M, Ejima A, Ohsuki S, Uoto K, Mitsui I, Kawato Y, et al. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J Med Chem 1998; 41:2308-2318.
13. Luzzio MJ, Besterman JM, Emerson DL, Evans MG, Lackey K, Leitner PL, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 1995; 38:395-401.
14. Lackey K, Sternbach DD, Croom DK, Emerson DL, Evans MG, Leitner PL, et al. Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. J Med Chem 1996; 39:713-719.
15. Vladu B, Woynarowski JM, Manikumar G, Wani MC, Wall ME, Von Hoff DD, et al. 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol Pharmacol 2000; 57:243-251.
16. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin Jr AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002; 99:15387-15392.
17. Dallavalle S, Ferrari A, Biasotti B, Merlini L, Penco S, Gallo G, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potential in vitro and in vivo antitumor activity. J Med Chem 2001; 44:3264-3274.
18. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65:635-692.
19. Champoux JJ. DNA topoisomerases: structure, function and mechanism. Annu Rev Biochem 2001; 70:369-413.
20. Pommier Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998; 80:255-270.
21. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 1989; 49:6318-6323.
22. Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol 2004; 67:1035-1045.
23. Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, et al. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol 2003; 65:1281-1294.
24. De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 2001; 61:7189-7195.
25. Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 2002; 8:3904-3909.
26. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, et al. A novel 7-modified camptothecin analog overcomes BCRP-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 2001; 61:6034-6037.
27. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhangen G, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938-5946.
28. Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1998; 1400:301-319.
29. Di Francesco AM, Meco D, Pisano C, Carminati P, Rutella S, D'Incalci M, et al. Antitumor activity of the novel 7-substituted camptothecin ST1481 (Gimatecan) against the human neuroblastoma SK-N-DZ. Proc Am Ass Cancer Res 2003; 44:811.
30. Pratesi G, De Cesare M, Veneroni S, Zunino F. Efficacy of Gimatecan (ST1481) in intracranial human tumor xenografts. Proc Am Ass Cancer Res 2003; 44:1791.
31. Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 1999; 44:411-416.
32. Xiao D, Tan W, Li M, Ding J. Antiangiogenic potential of 10-hydroxycamptothecin. Life Sci 2001; 69:1619-1628.
33. Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer 2002; 98:36-41.
34. Chiou W-F, Chou C-J, Chen C-F. Camptothecin suppresses nitric oxide biosynthesis in RAW 264.7 macrophages. Life Sci 2001; 69:625-635.
35. Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, et al. Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 2003; 1:863-870.
36. Gianni L, Hess D, Baselga J, Molossi A, Cresta S, Zucchetti M, et al. A phase I study of the oral camptothecin gimatecan with a design of concerted dose escalation in three schedules of different dosing-duration. Proc Am Soc Clin Oncol 2003; 22:554.
37. Alderson L, Supko J, Maestri X, Sampath P, Benincasa N, Belonogova N, et al. Phase I/II trial of gimatecan in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol 2003; 22:416.
38. Zhu AX, Ready NE, Clark JW, Safran H, Lynch TJ, Carminati P, et al. Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Proc Am Ass Clin Oncol 2003; 22:139.
39. Zucchetti M, Pace S, Frapolli R, Vannucchi J, Carminati P, Zanna C, et al. Clinical pharmacokinetic profile of gimatecan (ST1481), a new oral camptothecin derivative. Proc Am Soc Clin Oncol 2002; 21:476.